The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report.
Gordon Bl, Keenan Jp
Abstract
Gordon Bl, Keenan Jp
Abstract
A 23-year-old woman with a nine-month history of SLE, uncontrolled with high daily doses of steroids, was treated with the T-cell immunostimulant drug, levamisole. Following a single oral three-day course of therapy with this agent her immunologic parameters and clinical manifestations underwent marked regression. Continuous two-weekly course of this drug at three days per course have allowed rapid reduction of her steroid and resulted in complete remission of her symptoms. The theoretical considerations for the use of levamisole dovetailed perfectly with the observed response to this agent.
OpenAlex reports 27 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A 23-year-old woman with a nine-month history of SLE, uncontrolled with high daily doses of steroids, was treated with the T-cell immunostimulant drug, levamisole. Following a single oral three-day course of therapy with this agent her immunologic parameters and clinical manifestations underwent marked regression. Continuous two-weekly course of this drug at three days per course have allowed rapid reduction of her steroid and resulted in complete remission of her symptoms. The theoretical considerations for the use of levamisole dovetailed perfectly with the observed response to this agent.
Key concepts: Levamisole, Immunostimulant, Medicine, Drug, Internal medicine, Drug treatment, Lupus erythematosus, Immunology